Compare OFG & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFG | URGN |
|---|---|---|
| Founded | 1964 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2012 | 2016 |
| Metric | OFG | URGN |
|---|---|---|
| Price | $52.49 | $43.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $45.17 | $29.29 |
| AVG Volume (30 Days) | 205.4K | ★ 563.5K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ 8.27 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $11.56 | $129.09 |
| Revenue Next Year | $1.29 | $70.96 |
| P/E Ratio | $19.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.71 | $15.86 |
| 52 Week High | $54.47 | $50.81 |
| Indicator | OFG | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 47.05 |
| Support Level | $51.46 | $42.00 |
| Resistance Level | $53.90 | $43.93 |
| Average True Range (ATR) | 0.89 | 2.00 |
| MACD | -0.06 | -0.21 |
| Stochastic Oscillator | 58.06 | 33.84 |
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.